MIMEDX takes platinum sponsor role at limb salvage conference The company will present new wound care data at SAWC and join multidisciplinary teams at MedStar’s DLS meeting focused on patients at risk of amputation.

#MDXG MIMEDX to Sponsor Leading Advanced Wound Care Conferences

www.stocktitan.net/news/MDXG/mimedx-to-spon...

MIMEDX Announces Launch of CHORIOFIX™ MiMedx (Nasdaq: MDXG) announced the commercial launch of CHORIOFIX on March 23, 2026, a lyophilized placental allograft composed of two chorion layers with an intact intermediate layer.The company said CHORIOFIX is its thickest product to date, designed to improve handling, positioning and suturing, and has been added to the prospective randomized CAMPAIGN trial to evaluate performance versus standard of care in non-healing diabetic foot ulcers.

#MDXG MIMEDX Announces Launch of CHORIOFIX™

www.stocktitan.net/news/MDXG/mimedx-announc...

MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields MiMedx (Nasdaq: MDXG) launched AMNIOFIX Thyroid Shields, a DHACM allograft line for endocrine surgery designed to protect the recurrent laryngeal nerve and parathyroid glands after thyroidectomy.The product is preconfigured for operating-room use, shelf-stable up to five years, manufactured with the PURION process, and supported by a retrospective single-center study showing a 76% reduction in 24-hour RLN damage (3.4% vs 14.4%, p<0.01).

#MDXG MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields

www.stocktitan.net/news/MDXG/mimedx-expands...

MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel MiMedx (Nasdaq: MDXG) entered an exclusive U.S. distribution agreement with Regen Lab USA to distribute RegenKit®-Wound Gel, an autologous PRP and autologous thrombin serum wound gel, on Dec 22, 2025. The product concentrates growth factors, platelets, plasma proteins and nutrients in a fibrin scaffold and removes iron-laden red blood cells.RegenKit was approved by FDA in 2022 and is covered nationally by CMS/LCD for diabetic chronic wounds under HCPCS code G0465. MiMedx says the kit adds a differentiated autologous option to its Advanced Wound Care portfolio and that upcoming LCD implementation on Jan 1, 2026 strengthens its competitive position.

#MDXG MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel

www.stocktitan.net/news/MDXG/mimedx-enters-...

MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro MiMedx (NASDAQ: MDXG) announced a peer-reviewed publication on Dec 19, 2025 in the Journal of Inflammation reporting in vitro findings for Purion processed dehydrated (DHACM) and lyophilized (LHACM) human amnion chorion membrane allografts.The study found that DHACM and LHACM exhibit multifactorial immunomodulatory effects on inflammatory monocytes and macrophages and enhance pro-reparative functions including efferocytosis and cell survival, suggesting potential to help reset the wound-healing cascade in complex wounds characterized by persistent inflammation.

#MDXG MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro

www.stocktitan.net/news/MDXG/mimedx-announc...

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial MiMedx (Nasdaq: MDXG) reported interim results from the CAMPAIGN randomized controlled trial evaluating EPIEFFECT versus standard of care (SOC) for nonhealing diabetic foot ulcers. The interim analysis (71 patients) showed a posterior probability of superiority of 98.5% against a 90% success threshold. Results were published in the International Journal of Tissue Repair and an expanded 88-patient sample was presented at TRES on Oct 30, 2025. Enrollment is ongoing and MiMedx highlighted potential relevance for pending Medicare and commercial LCD implementations effective Jan 1, 2026.

#MDXG MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial

www.stocktitan.net/news/MDXG/mimedx-provide...

Trade Alerts, Monday November 3, 2025 – Crystal Equity Research

Small-cap stocks in new uptrend according to ave directional index, Mon Nov 3rd - #URGN #MDXG #III #EVTV #BYSI #ADTN #PDS #MD #FRGE #CMRE - More: crystalequityresearch.com/trade-alerts... - #smallcap

MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and Medicaid Services (“CMS”) release of the CY 2026 Physician Fee Schedule (“PFS”)

#MDXG MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule

www.stocktitan.net/news/MDXG/mimedx-comment...

MIMEDX Announces Record Revenue for Third Quarter 2025 MIMEDX (Nasdaq: MDXG) reported record third-quarter 2025 results: net sales $114M (+35% YoY), GAAP net income $17M, diluted EPS $0.11, and adjusted EBITDA $35M (31% of net sales). Gross margin was 84% and cash and cash equivalents were $142M (net cash of $124M after debt). Management raised 2025 guidance to expect mid-to-high teens net sales growth and at least mid-20% full-year adjusted EBITDA margin. Company cited CMS 2026 reimbursement rules as an open factor and will host a conference call on Oct 29, 2025 at 4:30 PM ET.

#MDXG MIMEDX Announces Record Revenue for Third Quarter 2025

www.stocktitan.net/news/MDXG/mimedx-announc...

MIMEDX Announces Launch of EPIXPRESS® MiMedx (Nasdaq: MDXG) announced on October 6, 2025 the launch of EPIXPRESS, a next‑generation lyophilized human placental allograft added to its Advanced Wound Care portfolio.EPIXPRESS is a PURION®‑processed, thick tri‑layer product that adds fenestrations to improve fluid movement versus EPIEFFECT and is intended for acute and chronic hard‑to‑heal wounds including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), deep or tunneling wounds, and wounds requiring suture fixation.The company characterized the product as an organically developed, market‑driven innovation designed to expand clinician treatment options.

#MDXG MIMEDX Announces Launch of EPIXPRESS®

www.stocktitan.net/news/MDXG/mimedx-announc...

MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place

#MDXG MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall

www.stocktitan.net/news/MDXG/mimedx-to-spon...

Leading Indicators, Thursday July 31, 2025 – Crystal Equity Research

Small-cap stocks in new uptrend with AROON Oscillator, Thu Jul 31st - #XTIA #SNGX #PSHG #UDMY #SRTS #MDXG #DSGR #WLDS #CLMB #BLTE #ABUS #HYAC #SPH #ETD #ANVS - More: crystalequityresearch.com/leading-indi... - #smallcap

MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results MIMEDX (NASDAQ:MDXG) reported record-breaking Q2 2025 results with net sales of $99 million, marking a 13% year-over-year growth. The company achieved GAAP net income of $10 million ($0.06 per diluted share) and Adjusted EBITDA of $24 million (25% of net sales).Growth was driven by strong performance in both segments: Wound product sales increased 12%, supported by CELERA™ and EMERGE™ products, while Surgical products grew 15%, with notable contributions from AMNIOFIX®, AMNIOEFFECT®, and HELIOGEN™. The company ended the quarter with $119 million in cash, up $12 million.Based on strong performance, MIMEDX raised its 2025 guidance, now expecting low double-digit net sales growth and Adjusted EBITDA margin above 20%.

#MDXG MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results

www.stocktitan.net/news/MDXG/mimedx-announc...

MIMEDX Expands Wound Care Portfolio: 80% Healing Rate Technology Now Part of Strategic Alliance Strategic partnership combines MIMEDX's placental allografts with Vaporox's FDA-cleared device showing 80% wound healing success. Learn about exclusive acquisition rights.

#MDXG MIMEDX Announces Strategic Collaboration with Vaporox, Inc.

www.stocktitan.net/news/MDXG/mimedx-announc...

MIMEDX Comments on Proposed Medicare Reimbursement Rule Changes for CY 2026 MIMEDX (NASDAQ:MDXG) has responded to CMS's proposed CY 2026 Physician Fee Schedule changes regarding skin substitute reimbursement. The new proposal suggests replacing the current ASP methodology with a fixed price of $125.38 per square centimeter for all skin substitutes.The reform aims to address the dramatic increase in Medicare spending on skin substitutes, which surged from $1.5 billion in 2022 to nearly $10 billion in 2024. CEO Joseph H. Capper supports the reform, noting it will help combat fraud and unsavory business practices in the market.The changes, along with the WISeR model and pending LCDs, are scheduled for implementation on January 1, 2026. MIMEDX expects to maintain its competitive position due to its product capabilities and clinical evidence.

#MDXG MIMEDX Comments on Proposed Medicare Reimbursement Rule Changes for CY 2026

www.stocktitan.net/news/MDXG/mimedx-comment...

New Clinical Data: EPIFIX Cuts Mohs Surgery Recovery Time by 31%, Shows 97% Success Rate in Skin Cancer Treatment New study reveals EPIFIX reduces Mohs surgery complications by 18.5% and accelerates healing time. See how this breakthrough impacts 850,000 annual procedures. Get insights.

#MDXG MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)

www.stocktitan.net/news/MDXG/mimedx-announc...

MIMEDX Delivers 9% Revenue Growth in 2024: Can Their Momentum Continue? MIMEDX achieved $349M in 2024 revenue with 21% Q4 EBITDA margin and projects continued growth. Strong cash position of $104M supports expansion plans.

#MDXG MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results

www.stocktitan.net/news/MDXG/mimedx-announc...

MIMEDX Battles Patent Infringement: Files Major Lawsuit Over Placental Allograft Technology Leading biotech firm MIMEDX, with 70+ patents, takes legal action against Surgenex over alleged patent violations in placental allograft products. Stakes rise in biotech IP battle.

#MDXG MIMEDX Files Patent Infringement Lawsuit Against Surgenex

www.stocktitan.net/news/MDXG/mimedx-files-p...

Breaking News: ( NASDAQ: #MDXG ) MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs

#StockMarket #News

#MDXG MIMEDX’s Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs

www.stocktitan.net/news/MDXG/mimedx-s-advoc...